Program News
News and stories about the UNC Lineberger Cellular Immunotherapy Program
-
Serody and Yeh honored with Battle Distinguished Cancer Research Award
Jonathan Serody, MD, and Jen Jen Yeh, MD, were named the 2023 recipients of the Hyman L. Battle Distinguished Cancer Research Award, recognizing their significant scientific achievements.
-
Immune cell transformation can influence stem cell transplant success in cancer patients
Jonathan Serody, MD, Ian Davis, MD, PhD, and colleagues report ILC2s can change functions after a patient receives stem cells, thereby preventing a healthy rebuilding of the immune system.
-
Curated cancer care
UNC Lineberger researchers are using CAR-T to create better and personalized cancer treatments in one of the largest cell therapy facilities on the East Coast.
-
Thomas C. Shea Clinical Cancer Symposium brings together national leaders in blood cancers
The inaugural symposium featured talks on adoptive cellular therapy for lymphoid malignancies and novel approaches for the treatment of acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms.
-
Questions and answers about CAR-T therapy
CAR-T immunotherapy uses your body’s own immune system to help fight cancer. Jonathan Serody, MD, and Natalie Grover, MD, answer some common questions people have about this treatment.
-
Parents, supporters create new fund for CAR-T therapy
Inspired by the potential of immunotherapy in solid tumor cancers, Tom and Nancy Chewning established a fund to support Jonathan Serody, MD, and accelerate his work with CAR-T immunotherapy.
-
Engineered safety switch curbs severe side effects of CAR-T immunotherapy
As part of a study led by Matthew Foster, MD, the advance was seen in a patient enrolled in a clinical trial using CAR-T to treat refractory acute B-cell leukemia.
-
European Medicines Agency awards priority designation for Hodgkin lymphoma CAR-T therapy
The European Medicines Agency granted priority medicines designation to Tessa Therapeutics’ CD30 targeted CAR-T therapy for patients with relapsed or refractory Hodgkin lymphoma.